Diabetic Gastroparesis is a condition characterized by delayed gastric emptying, which is a common complication of diabetes. The condition is associated with a range of symptoms, including nausea, vomiting, abdominal pain, and bloating. The Global Diabetic Gastroparesis treatment market is expected to grow significantly in the coming years, driven by the increasing prevalence of diabetes and the growing demand for effective treatment options.
Diabetic Gastroparesis Market Size and Growth
According to a Expert Market Research report, the global diabetic gastroparesis treatment market is expected to reach a value of USD 3.8 billion by 2028, growing at a CAGR of 4.9% from 2023 to 2028. The market is expected to be driven by the increasing prevalence of diabetes, the growing geriatric population, and the rising demand for effective treatment options.
Geographical Analysis
The global diabetic gastroparesis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the market during the forecast period, owing to the high prevalence of diabetes in the region, the presence of key market players, and the increasing adoption of advanced treatment options. Asia Pacific is expected to witness significant growth during the forecast period, driven by the increasing prevalence of diabetes in the region, the growing geriatric population, and the rising demand for effective treatment options.
Market Segmentation
The global diabetic gastroparesis treatment market is segmented on the basis of treatment type, disease type, end-user, and region. On the basis of treatment type, the market is segmented into drugs and devices. The drugs segment is further segmented into prokinetic agents, antiemetics, and others. The devices segment is further segmented into gastric electric stimulators, botulinum toxin injections, and others.
On the basis of disease type, the market is segmented into idiopathic and diabetic gastroparesis. The diabetic gastroparesis segment is expected to dominate the market during the forecast period, owing to the high prevalence of diabetes worldwide.
On the basis of end-user, the market is segmented into hospitals, clinics, and others. The hospitals segment is expected to dominate the market during the forecast period, owing to the high patient inflow and the availability of advanced treatment options.
Key Players
The global diabetic gastroparesis treatment market is highly competitive, with the presence of several key players. Some of the key players operating in the market include Abbott Laboratories, Allergan Inc., Cadila Healthcare Ltd., Evoke Pharma Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Medtronic plc, Pfizer Inc., Salix Pharmaceuticals Inc., and Shire Plc. These players are focusing on developing advanced treatment options and expanding their product portfolios to strengthen their market position.
Recent Developments
Evoke Pharma Inc. announced that it had entered into an exclusive license agreement with Windlas Healthcare Pvt. Ltd. to commercialize Gimoti (metoclopramide) nasal spray in India.
Salix Pharmaceuticals Inc. announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its product, Rezipres, for the treatment of adults with symptomatic chronic idiopathic constipation (CIC).
Medtronic plc announced that it had received approval from the FDA for its product, the InterStim Micro neurostimulator and the InterStim SureScan MRI leads, for the treatment of overactive bladder and fecal incontinence.
Conclusion
The global diabetic gastroparesis treatment market is expected to grow significantly in the coming years, driven by the increasing prevalence of diabetes and the growing demand for effective treatment options.
